<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040464</url>
  </required_header>
  <id_info>
    <org_study_id>PI2021_843_0080</org_study_id>
    <nct_id>NCT05040464</nct_id>
  </id_info>
  <brief_title>Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial</brief_title>
  <acronym>COMET</acronym>
  <official_title>Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combination therapy, the association of an anti-Tumor Necrosis Factor (TNF) to an&#xD;
      immunosuppressant, is recognized as the most effective treatment during Crohn's disease (CD).&#xD;
      Several mechanisms have been proposed to explain the superiority of combination therapy over&#xD;
      monotherapy, the additive effect of two effective drugs or the prevention of anti-TNF&#xD;
      immunogenicity. As the best combination therapy is unknown, both azathioprine (AZA) and&#xD;
      methotrexate (MTX) are used. Some retrospective studies suggest a higher effectiveness of&#xD;
      AZA. MTX may have an advantage in terms of safety.&#xD;
&#xD;
      The investigators hypothesize that AZA is more effective than MTX as combination therapy with&#xD;
      adalimumab to improve short-term endoscopic, clinical and pharmacological outcomes in CD&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of the endoscopic response between AZA and MTX groups</measure>
    <time_frame>26 weeks</time_frame>
    <description>Variation of the endoscopic response to AZA in combination with adalimumab and to MTX in combination with adalimumab in patients with CD.&#xD;
The endoscopic reference score (EREFS) is used to determine severity of 5 endoscopic findings: edema, rings, exudates, furrows, and structures. The EREFS classification system rates the severity of edema (0-2), rings (0-3), exudates (0-2), furrows (0-2), and strictures (0-1)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Azathioprine</condition>
  <condition>Methotrexate</condition>
  <arm_group>
    <arm_group_label>AZA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of sub-cutaneous administration of adalimumab at a dose of 160mg(W0)-80mg(W2)-40mg(W6) and then 40mg EOW and oral AZA capsules at a daily dose of 2.5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTX group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of sub-cutaneous administration of adalimumab at a dose of 160mg (week (W) 0)-80mg(W2)-40mg(W6) and then 40mg EOW and sub-cutaneous MTX 25mg once a week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZA capsules</intervention_name>
    <description>oral AZA capsules at a daily dose of 2.5 mg per kilogram,</description>
    <arm_group_label>AZA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>MTX 25 mg SC once a week</description>
    <arm_group_label>MTX group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>The lab tests are: serum albumin, C-reactive protein, thrombocytosis and haemoglobin.</description>
    <arm_group_label>AZA group</arm_group_label>
    <arm_group_label>MTX group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients with age &gt; 18 years&#xD;
&#xD;
          -  Crohn's disease for at least 6 weeks,&#xD;
&#xD;
          -  Clinically active with CDAI &gt; 150&#xD;
&#xD;
          -  Active inflammation by endoscopy (CDEIS &gt; 4) at baseline&#xD;
&#xD;
          -  Not responder to conventional therapy or are intolerant to or have medical&#xD;
             contraindications for such therapies and initiating treatment with adalimumab&#xD;
&#xD;
          -  Patient followed in a center belonging to the GETAID network&#xD;
&#xD;
          -  Fertile men and women of childbearing potential included in the protocol should use&#xD;
             adequate methods of contraception according to study drug SMPCs.&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Short bowel syndrome, ostomy, symptomatic stricture, abscess, recent history of&#xD;
             abdominal surgery (&lt;3 months)&#xD;
&#xD;
          -  Non-passable colonic stricture&#xD;
&#xD;
          -  Previous intolerance to thiopurines or MTX&#xD;
&#xD;
          -  Previous exposition to adalimumab&#xD;
&#xD;
          -  Contra-indication to immunosuppressants or anti-TNF&#xD;
&#xD;
          -  Others serious simultaneous illness that could interfere with study participation&#xD;
&#xD;
          -  Planning pregnancy, pregnancy or lactation or absence of contraception&#xD;
&#xD;
          -  Known substance abusers&#xD;
&#xD;
          -  Use of any investigational drug within 30 days&#xD;
&#xD;
          -  Adults protected by law&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mathurin Fumery, Pr</last_name>
    <phone>03 22 08 88 51</phone>
    <email>Fumery.mathurin@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathurin Fumery, Pr</last_name>
      <phone>03 22 08 88 51</phone>
      <email>Fumery.mathurin@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Benjamin Pariente, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clea Rouillon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume Savoye, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vanessa Bonjemah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Duveau Nicolas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Painchart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tavernier Noemie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Peyrin-Biroulet, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoram Bouhnik, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Laharie, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud Boureille, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antony Buisson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucine Vuitton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain Altwegg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Roblin, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn Disease</keyword>
  <keyword>Combinations of therapy</keyword>
  <keyword>anti-Tumor Necrosis Factor</keyword>
  <keyword>azathioprine</keyword>
  <keyword>methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

